AQUESTIVE THERAPEUTICS INC (AQST)
Health Care · Specialty Pharmaceuticals · NASDAQ
Aquestive Therapeutics develops advanced, non-invasive pharmaceutical delivery technologies and products, with a primary focus on its oral epinephrine prodrug candidates for severe allergic reactions.
What AQUESTIVE THERAPEUTICS INC does
Aquestive Therapeutics is a pharmaceutical company that develops and manufactures therapeutic products using its proprietary film-based drug delivery technologies, such as PharmFilm. The company focuses on advancing late-stage, non-invasive product candidates, including epinephrine treatments for severe allergic reactions and epilepsy therapies, while also manufacturing licensed products for other companies.
Recent developments
Aquestive completed the required human factors and pharmacokinetic studies for Anaphylm in Q2 2026 to address prior FDA deficiencies and expects to resubmit the NDA in Q3 2026. Additionally, the company is advancing its AQST-108 topical gel program into new dermatological indications like atopic dermatitis.
From AQUESTIVE THERAPEUTICS INC's filing of 2026-08-11.
Themes: drug delivery platform, epinephrine / allergy rescue, epilepsy treatments, dermatology, orphan drugs
Fundamentals
- Price$4.08 as of 2026-10-21 close
- Market cap$512M as of 2026-08-07 (share count; price 2026-10-21)
- 1-year return-42.0% 2025-10-21 close $7.04 → 2026-10-21 close $4.08
- P/En/a negative earnings
- Net margin-188.1% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its stockholders' equity is zero or negative, where the ratio means nothing.
- Revenue growth (YoY)-22.6% FY2025, SEC XBRL
- Revenue CAGR (3y)-2.2% SEC XBRL
- Beta1.22 as of 2026-09-03
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How AQST compares in its sector
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $14M | -$8M | -$23M | -$0.18 | -$9M† | $212000† |
| Q1 FY2026 2026-03-31 | $14M | -$4M | -$8M | -$0.07 | -$15M | $52000 |
| Q4 FY2025 2025-12-31 | $13M† | -$29M† | -$32M† | -$0.27† | -$8M† | $85000† |
| Q3 FY2025 2025-09-30 | $13M | -$11M | -$15M | -$0.14 | -$13M† | $235000† |
| Q2 FY2025 2025-06-30 | $10M | -$11M | -$14M | -$0.14 | -$8M† | $107000† |
| Q1 FY2025 2025-03-31 | $9M | -$19M | -$23M | -$0.24 | -$23M | $135000 |
| Q4 FY2024 2024-12-31 | $12M† | -$14M† | -$17M† | -$0.19† | -$6M† | $15000† |
| Q3 FY2024 2024-09-30 | $14M | -$8M | -$12M | -$0.13 | -$12M† | $80000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$98M
- Total debt$55M borrowings only; leases excluded
- Net debt-$43M total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How AQUESTIVE THERAPEUTICS INC looks technically
AQUESTIVE THERAPEUTICS INC (AQST) is trading 4.4% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 22 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 38, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 6 trading days ago (its momentum flipped negative). It made a new 20-day low about 4 trading days ago. It is 46.0% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 4.4% below its 200-day average, the long-term trend line — a long-term downtrend | -4.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.70 | $4.70 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $4.27 | $4.27 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 12 calendar days ago — the swings before that are what the structure reading is measured on | 12 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 4.975. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 22 trading days ago — a "golden cross", a bullish long-term signal | 22 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend) | 20.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 38, neither overbought (above 70) nor oversold (below 30) | 38.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($3.65 to $4.97) — its "stochastic" reading is 32 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 32.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 6 trading days ago (its momentum flipped negative) | 6 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $7.55 | $7.55 |
|---|---|---|
| From the 52-week high | it is 46.0% below its 52-week high (its highest price of the past year) | -46.0% |
| Above the 52-week low | it is 39.2% above its 52-week low (its lowest price of the past year) | +39.3% |
| Below the 52-week high | it is 46.0% below its highest point of the past year | 46.0% |
| Since a 20-day breakout | it made a new 20-day low about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day high about 40 trading days ago | 40 sessions |
| All-time high | its highest closing price on record is $20.70 (set on 2018-09-13) | $20.70 |
| Given back of the 52-week move | over the past year its closes ranged ($2.95 to $7.49), and it has recovered roughly a quarter of its fall from last year’s high — 25% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $5.76 to $5.90. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 24.9% |
| From the all-time high | it is 80.3% below its all-time high | -80.3% |
| Nearest price level | it is trading 2.0% above a support level at $4.00 — a price it turned at twice since 2026-04-29, most recently on 2026-05-18. Since 2024-10-21 it has 8 such levels below the current price and 7 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.0% |
| All-time low | its lowest closing price on record is $0.618 (set on 2022-07-01) | $0.618 |
| Above the all-time low | it is 560.2% above its all-time low | +560.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 79% of it) | 79th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2491 between its high and its low — about 6.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2491 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.84 and $5.14 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.84 – $4.49 – $5.14 |
| Typical daily range (% of price) | its price moves about 6.1% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.1% |
| Stretch from the 200-day average | it is trading 0.8 daily ranges below its 200-day average price (4.4% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.66× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a hammer | 2 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 2 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-21 0.7% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.7% |
|---|---|---|
| Gap filled | a 2.0% gap up opened on 2026-10-02 has been "filled" 13 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 13 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +7.94% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 14.6 percentage points (the stock lost 14.6% while the market lost 0.1%) | -14.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 2.3 percentage points (the stock gained 1.0% while the market gained 3.3%) | -2.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 15.8 percentage points (the stock lost 6.0% while the market gained 9.8%) | -15.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 57.2 percentage points (the stock lost 42.0% while the market gained 15.2%) | -57.2% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 9.8% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 9.5% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -9.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 2% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $4.18 — a volume-weighted average of daily closes over 199 sessions, not a true tick-by-tick VWAP. | -2.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 12% below the average price paid since it last reported on 2026-08-11 (its 10-Q), so the typical buyer over that stretch is under water. That average is $4.61 — a volume-weighted average of daily closes over 51 sessions, not a true tick-by-tick VWAP. | -11.5% |
Price levels it has turned at before
AQST last closed at $4.08 on 2026-10-21. Since 2024-10-21 it has turned at 8 prices below its last close and 7 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $4.00 | Support | 2.0% below the last close | turned there twice · 2026-04-29 to 2026-05-18 |
| $4.28 | Resistance | 5.0% above the last close | turned there three times · 2025-08-12 to 2026-04-08 |
| $3.82 | Support | 6.4% below the last close | turned there three times · 2025-01-02 to 2026-06-03 |
| $4.39 | Resistance | 7.7% above the last close | turned there five times · 2024-11-18 to 2026-10-02 |
| $3.73 | Support | 8.6% below the last close | turned there four times · 2025-08-01 to 2026-03-24 |
| $4.50 | Resistance | 10.3% above the last close | turned there three times · 2025-07-18 to 2026-09-18 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $4.97.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $3.87 and $4.29 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $4.97.
This reading has stood for 4 trading days, since 2026-10-16.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Recent golden cross (50-day crossed above 200-day) · Pulled back from the 12-month high · lagging the market · Printed a doji candle | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.22 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$9.33 range $6.00 – $11.00; median $10.00
Analyst estimates, as of 2026-10-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AQST
- Consensus EPS estimate-$0.135 next reporting period, as of 2026-10-19
- Estimate change, 30 days$0.00 from -$0.135, on 2026-09-15, 34-day window
- Readings revised upward0% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on regulatory approval for key product candidates like Anaphylm, which previously received a Complete Response Letter.","Significant indebtedness and potential future financial obligations that could limit operational flexibility or require additional capital.","Substantial reliance on a small number of licensed products for current revenue, creating risks if those products face generic competition or market decline."]
What changed in the latest 10-Q
AI-assisted comparison of AQST's 10-Q filed 2026-08-11 against the prior one filed 2026-05-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (filed 2026-08-11) added forward-looking statement language: 'anticipated timelines, milestones, and guidance relating to regulatory submissions, clinical studies, regulatory interactions, and potential approvals, which are subject to change based on regulatory feedback, protocol alignment, data sufficiency, and other factors outside the Company's control;'
- Newer filing (filed 2026-08-11) added risk factor language: 'risks related to our existing indebtedness and potential future obligations under our Credit Agreement, including the risk that, should Anaphylm receive FDA approval, our indebtedness will increase substantially, and there is no assurance that revenues from the commercialization of Anaphylm will be sufficient to service or repay such obligations; and that, if Anaphylm does not receive FDA approval, we will be required to maintain larger cash reserves to fund ongoing operations and will not be able to deploy those funds for other purposes;'
- Newer filing (filed 2026-08-11) added risk factor language: 'risks that restrictive covenants contained in our Credit Agreement could limit our operational flexibility, including restrict our ability to incur additional indebtedness or make investments, and impair our ability to raise additional capital when needed;'
- Removed:
- Older filing (filed 2026-05-13) contained risk factor language that is absent from the newer filing: 'risk that our manufacturing capabilities will be insufficient to support demand of our product candidates in the U.S. and abroad, including Anaphylm, if such product candidates should be approved by the FDA and other regulatory authorities, and our licensed products in the U.S. and abroad; risk of eroding market share for Suboxone ® as a sunsetting product, which accounts for a substantial part of our current operating revenue; risk of default of our debt instruments; risks related to the outsourcing of certain sales, marketing and other operational and staff functions to third parties; risk of the rate and degree of market acceptance in the U.S. and abroad of Anaphylm, AQST-108, Libervant and our other product candidates, should these product candidates be approved by the FDA and other regulatory authorities, and for our licensed products in the U.S. and abroad; risk associated with the size and growth of our product markets; risk associated with our compliance with all FDA and other governmental and customer requirements for our manufacturing facilities; risks associated with intellectual property rights and infringement cl'
- Reworded:
- Newer filing (filed 2026-08-11) changed Anaphylm description from 'oral administration of epinephrine' to 'non-invasive orally delivered epinephrine product' in the forward-looking statements.
- Newer filing (filed 2026-08-11) changed AQST-108 indication language from 'the targeted indication of alopecia areata' to 'the indication of alopecia areata and atopic dermatitis' in the forward-looking statements.
- Newer filing (filed 2026-08-11) changed 'any of these product candidates' to 'any for these product candidates' regarding failure to receive FDA approval.
- Notes:
- The newer filing text appears truncated at 'risk that our m' and the older filing text appears truncated at 'risks associated with intellectual property rights and infringement cl', so the full risk factor text beyond the truncation points could not be compared.
Risk Factors
- Added:
- Newer filing (2026-08-11) references 'subsequent Quarterly Reports on Form 10-Q' in the Risk Factors incorporation statement; older filing (2026-05-13) references only the 2025 Annual Report on Form 10-K.
- Newer filing (2026-08-11) includes Risk Factors text stating reliance on third parties to manufacture API for licensed products and product candidates.
- Reworded:
- Risk Factors incorporation language changed from referencing only 'Part I, Item 1A of Aquestive's 2025 Annual Report on Form 10-K' in the older filing (2026-05-13) to referencing 'Part I, Item 1A of Aquestive's 2025 Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q' in the newer filing (2026-08-11).
- Older filing (2026-05-13) contains full text of a risk factor about reliance on third-party API manufacturers; newer filing (2026-08-11) does not contain this full text in the Risk Factors section.
- Notes:
- The provided newer-filing extract appears truncated immediately after Item 1A and jumps to Item 2; if the third-party API manufacturer risk factor text was present but omitted from the supplied extract, that could alter the comparison.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 4 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-17. The 5 days since 2026-10-17 have not been checked yet.
- Last 30 days · read to 2026-10-170 buys · 1 sell ($105600) — 1 selling insider
- Last 90 days · read to 2026-10-170 buys · 4 sells ($378930) — 2 selling insiders
- Last 180 days · read to 2026-10-170 buys · 9 sells ($743938) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-15. Based on Form 4 filings read through 2026-10-17; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AQST's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding AQST as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 12,841,257
- Reported value $53,419,629
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about AQST's institutional holders → See what each manager we track holds →
Short interest (FINRA)
AQST had 28,748,212 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
AQST had 22.9% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 13.06 days to cover at the same settlement.
- Reported short interest (shares) 28,748,212
- Short interest (% of shares outstanding) 22.9%
- Prior settlement (shares) 27,161,738
- Reported change 5.84%
- Days to cover (reported) 13.06
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Teva Pharmaceutical Industries (TEVA)
- Viatris (VTRS)
- Amneal Pharmaceuticals (AMRX)
- Kaleo
- U.S. WorldMeds
- ARS Pharmaceuticals (SPRY)
- ALK-Abello A/S
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AQST vs…
AQUESTIVE THERAPEUTICS INC is found in…
Frequently asked questions
What does AQUESTIVE THERAPEUTICS INC (AQST) do?
Aquestive Therapeutics is a pharmaceutical company that develops and manufactures therapeutic products using its proprietary film-based drug delivery technologies, such as PharmFilm. The company focuses on advancing late-stage, non-invasive product candidates, including epinephrine treatments for severe allergic reactions and epilepsy therapies, while also manufacturing licensed products for other companies.
What sector is AQUESTIVE THERAPEUTICS INC (AQST) in?
AQUESTIVE THERAPEUTICS INC (AQST) is classified in the Health Care sector. Its industry is Specialty Pharmaceuticals. It trades on NASDAQ.
Who are AQUESTIVE THERAPEUTICS INC's (AQST) competitors?
Notable peers of AQUESTIVE THERAPEUTICS INC (AQST) include Teva Pharmaceutical Industries, Viatris, Amneal Pharmaceuticals, Kaleo and U.S. WorldMeds. This peer set is informational only — not financial advice.
Is AQUESTIVE THERAPEUTICS INC (AQST) overbought or oversold right now?
AQUESTIVE THERAPEUTICS INC (AQST) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 38, in the neutral middle (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AQST come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.